GETUG-AFU 15

Cancer de Prostata

1. GETUG – AFU 15 Dr. Daniel Agüero Velásquez Residente Oncología Médica 2016

2. The Hypothesis Do c et a xe l a d d ed at the t i me o f sta r ti n g ADT in ho rm o n e- se n sit i ve met as t at i c pros t ate c a nce r (mH S P C ) will pro l ong o v era ll s ur v iv a l (O S )

3. Meta s tatic HSPC: GETUG 1 5 T rial D esign n = 385 pts A D T : LHRH a g o n ist or m axi m um a n dr o g e n blo c ka d e or orchiect o my 75 mg/ m 2 q3 u p to 9 c y cles Gr a v is G, et al. Lan c et Oncol. 2013; 1 4 (2): 14 9 - 1 58 . 1 Glass TR , et al. J U r o l . 2003 ; 169(1 ): 16 4 - 1 6 9.

4. Median PF S : A D T + D : 23 mo [ 19.6-28. 4 ] AD T : 13 mo [ 1 1. 9 -17.7] H R [95 % CI]: . 72 [0.57-0. 9 1] P = .0052 A D T+ doce t axel ADT A DT A DT+ docetaxel Gr a v is G, et al. Lan c et Oncol. 2013; 1 4 (2): 14 9 - 1 58 . Biochemical Progressio n -Free S urvival :

5. Me d ian cPF S : AD T + D : 23 mo [ 2 . 5 -32] AD T : 15 mo [ 12. 5 - 20] H R [ 9 5 % C I]: 0.75 [ .5 9 -0. 9 4] P = .01 4 7 A D T+ doce t axel ADT Cli n ical Progressi o n -Free S urvival : A DT A DT+ docetaxel Gr a v is G, et al. Lan c et Oncol. 2013; 1 4 (2): 14 9 - 1 58 .

6. Med i an O S : A D T + D : 59 mo [ 51 - 69] AD T : 54 mo [ 42- NR ] HR [95 % CI]: 1 . 01 [0.7 5 -1. 3 6] P = .95 A D T + doce t axel ADT A DT A DT + docetax e l Median fo l lo w - u p: 50 mont h s [49 - 54] Overall Survival Gr a v is G, et al. Lan c et Oncol. 2013; 1 4 (2): 14 9 - 1 58 .